Nicola Tambasco

Dr. Nicola Tambasco

Azienda Ospedaliera e Universitaria di Perugia
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2010 in The Lancet Neurology
Verified
Journal Article
Closed access
PCPaolo Calabresi
Paolo Calabresi
MFMassimiliano Di Filippo
Massimiliano Di Filippo
VGVeronica Ghiglieri
Veronica Ghiglieri
Nicola TambascoNicola Tambasco
Nicola Tambasco
Barbara PicconiBarbara Picconi
Barbara Picconi

16 January 2014 in Movement Disorders
Verified
Journal Article
Open access
PDF file
Parnetti LucillaParnetti Lucilla
Parnetti Lucilla
DCDavide Chiasserini
Davide Chiasserini
EPEmanuele Persichetti
Emanuele Persichetti
PEPaolo Eusebi
Paolo Eusebi
SVShiji Varghese
Shiji Varghese
PCPaolo Calabresi
Paolo Calabresi
To assess the discriminating power of multiple cerebrospinal fluid (CSF) biomarkers for Parkinson's disease (PD), we measured several proteins playing an important role in the disease pathogenesis. The activities of β‐glucocerebrosidase and other lysosomal enzymes, together with total and oligomeric α‐synuclein, and total and phosphorylated tau, were thus assessed in CSF of 71 PD patients and compared to 45 neurological controls. Activities of β‐glucocerebrosidase, β‐mannosidase, β‐hexosaminidase, and β‐galactosidase were measured with established enzymatic assays, while α‐synuclein and tau biomarkers were evaluated with immunoassays. A subset of PD patients (n = 44) was also screened for mutations in the β‐glucocerebrosidase‐encoding gene (GBA1). In the PD group, β‐glucocerebrosidase activity was reduced (P < 0.05) and patients at earlier stages showed lower enzymatic activity (P < 0.05); conversely, β‐hexosaminidase activity was significantly increased (P < 0.05). Eight PD patients (18%) presented GBA1 sequence variations; 3 of them were heterozygous for the N370S mutation. Levels of total α‐synuclein were significantly reduced (P < 0.05) in PD, in contrast to increased levels of α‐synuclein oligomers, with a higher oligomeric/total α‐synuclein ratio in PD patients when compared with controls (P < 0.001). A combination of β‐glucocerebrosidase activity, oligomeric/total α‐synuclein ratio, and age gave the best performance in discriminating PD from neurological controls (sensitivity 82%; specificity 71%, area under the receiver operating characteristic curve = 0.87). These results demonstrate the possibility of detecting lysosomal dysfunction in CSF and further support the need to combine different biomarkers for improving the diagnostic accuracy of PD. © 2014 International Parkinson and Movement Disorder Society

19 February 2013 in Nature Reviews Neurology
Verified
Journal Article
Closed access
PDF file
Parnetti LucillaParnetti Lucilla
Parnetti Lucilla
ACAnna Castrioto
Anna Castrioto
DCDavide Chiasserini
Davide Chiasserini
EPEmanuele Persichetti
Emanuele Persichetti
Nicola TambascoNicola Tambasco
Nicola Tambasco
PCPaolo Calabresi
Paolo Calabresi

26 August 2017 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
Parnetti LucillaParnetti Lucilla
Parnetti Lucilla
SPSilvia Paciotti
Silvia Paciotti
PEPaolo Eusebi
Paolo Eusebi
ADAndrea Dardis
Andrea Dardis
SZStefania Zampieri
Stefania Zampieri
TBTommaso Beccari
Tommaso Beccari

31 March 2014 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PDF file
Parnetti LucillaParnetti Lucilla
Parnetti Lucilla
LFLucia Farotti
Lucia Farotti
PEPaolo Eusebi
Paolo Eusebi
DCDavide Chiasserini
Davide Chiasserini
CCClaudia De Carlo
Claudia De Carlo
PCPaolo Calabresi
Paolo Calabresi
There is a great interest in developing cerebrospinal fluid (CSF) biomarkers for diagnosis and prognosis of Parkinson's disease (PD). CSF alpha synuclein (α-syn) species, namely total and oligomeric α-syn (t-α-syn and o-α-syn), have shown to be of help for PD diagnosis. Preliminary evidences show that the combination of CSF t-α-syn and classical Alzheimer's disease (AD) biomarkers—β-amyloid 1–42 (Aβ42), total tau (t-tau), phosphorylated tau (p-tau)—differentiate PD patients from controls, and that reduced levels of Aβ42 represent a predictive factor for development of cognitive deterioration in PD. In this prospective study carried out in 44 PD patients and 25 neurological controls we wanted to verify whether the combination of CSF α-synuclein species—t-α-syn and o-α-syn—and classical AD biomarkers may help in differentiating PD from neurological controls, and if these biomarkers may predict cognitive decline. The median of follow-up duration was 3 years (range: 2–6 years). Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) were used for monitoring cognitive changes along time, being administered once a year. Oligo/total α-syn ratio (o/t-α-syn ratio) confirmed its diagnostic value, significantly contributing to the discrimination of PD from neurological controls. A greater diagnostic accuracy was reached when combining o/t-α-syn and Aβ42/tau ratios (Sens = 0.70, Spec = 0.84, AUC = 0.82; PPV = 0.89, NPV = 0.62, LR+ = 4.40, DOR = 12.52). Low CSF Aβ42 level was associated with a higher rate of MMSE and MoCA decline, confirming its role as independent predictive factor for cognitive decline in PD. None of the other biomarkers assessed (t-tau, p-tau, t-α-syn and o-α-syn) showed to have prognostic value. We conclude that combination of CSF o/t-α-syn and Aβ42/tau ratios improve the diagnostic accuracy of PD. PD patients showing low CSF Aβ42 levels at baseline are more prone to develop cognitive decline.

1 November 2008 in Biological Psychiatry
Verified
Journal Article
Closed access
Parnetti LucillaParnetti Lucilla
Parnetti Lucilla
PTPietro Tiraboschi
Pietro Tiraboschi
ALAlessia Lanari
Alessia Lanari
MPMaria Peducci
Maria Peducci
CPChiara Padiglioni
Chiara Padiglioni
PCPaolo Calabresi
Paolo Calabresi